Cargando…

Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors

Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) exploit the concept of synthetic lethality and offer great promise in the treatment of tumors with deficiencies in homologous recombination (HR) repair. PARPi exert antitumor activity by blocking Poly(ADP-ribosyl)ation (PARylation) and trapping...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chu, Yu-Yi, Yam, Clinton, Yamaguchi, Hirohito, Hung, Mien-Chie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594904/ https://www.ncbi.nlm.nih.gov/pubmed/36284291 http://dx.doi.org/10.1186/s12929-022-00870-7

Ejemplares similares

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
por: Hodgson, Darren R., et al.
Publicado: (2018)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

CDK4/6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: Are we at the finish line?
por: Yam, Clinton, et al.
Publicado: (2018)

PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
por: Frizzell, Kristine M, et al.
Publicado: (2009)

PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
por: Menezes, Maria Clara Saad, et al.
Publicado: (2022)

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
por: Mei, Ying, et al.
Publicado: (2022)

Regulation and Role of EZH2 in Cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2014)

EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2017)

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance
por: Soung, Young-Hwa, et al.
Publicado: (2023)

Mechanism of PARP inhibitor resistance and potential overcoming strategies
por: Fu, Xiaoyu, et al.
Publicado: (2023)

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors
por: O’Sullivan, Ciara C., et al.
Publicado: (2014)

PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
por: Miller, Rowan E, et al.
Publicado: (2022)

Regulation of Ubiquitination-Mediated Protein Degradation by Survival Kinases in Cancer
por: Yamaguchi, Hirohito, et al.
Publicado: (2012)

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
por: Criscuolo, Daniela, et al.
Publicado: (2019)

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
por: Du, Yi, et al.
Publicado: (2016)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex
por: Chu, Yu-Yi, et al.
Publicado: (2022)

Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
por: Nicoletto, Maria Ornella, et al.
Publicado: (2023)

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
por: Castroviejo‐Bermejo, Marta, et al.
Publicado: (2018)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them
por: Kim, Dongha, et al.
Publicado: (2022)

Beyond NF-κB activation: nuclear functions of IκB kinase α
por: Huang, Wei-Chien, et al.
Publicado: (2013)

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
por: Wang, Qiwei, et al.
Publicado: (2022)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

Herbal Compounds Dauricine and Isoliensinine Impede SARS-CoV-2 Viral Entry
por: Dabrell, Shaneek Natoya, et al.
Publicado: (2023)

Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
por: Ray-Coquard, Isabelle, et al.
Publicado: (2020)

Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape
por: Prados-Carvajal, Rosario, et al.
Publicado: (2021)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
por: Dziadkowiec, Karolina N., et al.
Publicado: (2017)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors
por: Petrelli, Annalisa, et al.
Publicado: (2023)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
por: De Soto, Joseph A., et al.
Publicado: (2006)

Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models
por: Nguyen, Lily L., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_735anp9s1sfnio6dsm24d9sla5